Document Detail


Comparison of the degree of duodenogastroesophageal reflux and acid reflux between patients who failed to respond and those who were successfully treated with a proton pump inhibitor once daily.
MedLine Citation:
PMID:  19491829     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: The objective of this study was to compare the degree of esophageal acid exposure and duodenogastroesophageal reflux (DGER) during treatment between gastroesophageal reflux disease (GERD) patients who responded fully to proton pump inhibitor (PPI) once a day and those who failed to respond. METHODS: Gastroesophageal reflux disease patients who continued to report symptoms 3 times a week for 3 months while on PPI once a day were assigned to the PPI failure group. GERD patients who were asymptomatic on PPI once a day for 3 months were assigned to the PPI success group. All patients underwent upper endoscopy to assess esophageal mucosal injury. Subsequently, all patients underwent simultaneous 24-h esophageal Bilitec 2000 and pH testing while on treatment. Patients recorded GERD-related symptoms during the test. RESULTS: Twenty-four patients were enrolled in the PPI failure group and 23 patients were enrolled in the PPI success group. Endoscopy was normal in 63% of PPI failure patients and 76% of PPI success patients. Abnormal DGER was documented in 82% of PPI success patients vs. 67% of PPI failure patients (P=NS). All pH testing and Bilitec parameters in the PPI failure group were similar to those in the PPI success group (P=NS). Of the 34 GERD symptoms recorded by the PPI failure group, 64% were associated with acid reflux and 41% were associated with DGER (P<0.05). CONCLUSIONS: There is no difference in the degree of DGER and acid exposure during treatment between patients who failed to respond and those who achieved complete symptom resolution on PPI once daily. GERD symptoms in the PPI failure group are more commonly associated with acid reflux than with DGER.
Authors:
Anita Gasiorowska; Tomas Navarro-Rodriguez; Christopher Wendel; Elizabeth Krupinski; Zvi H Perry; Kristina Koenig; Bridget Moty; Jeannette Powers; Ronnie Fass
Related Documents :
8147349 - Are esophageal symptoms reflux-related? a study of different scoring systems in a cohor...
11805419 - Megaprepuce associated with vesicoureteric reflux.
9807069 - Correlation of laryngeal and pharyngeal carcinomas and 24-hour ph monitoring of the eso...
15858119 - A study to determine plasma antioxidant concentrations in patients with barrett's oesop...
22985259 - Role of peroxynitrite-modified h2a histone in the induction and progression of rheumato...
8432439 - Role of intragastric and intraoesophageal alkalinisation in the genesis of complication...
17095409 - Continuous eeg-sep monitoring of severely brain injured patients in nicu: methods and f...
1787489 - Sjögren's syndrome in patients with the crest variant of progressive systemic sclerode...
12136899 - Functional impairment in spondyloarthropathy and fibromyalgia.
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't     Date:  2009-06-02
Journal Detail:
Title:  The American journal of gastroenterology     Volume:  104     ISSN:  1572-0241     ISO Abbreviation:  Am. J. Gastroenterol.     Publication Date:  2009 Aug 
Date Detail:
Created Date:  2009-08-07     Completed Date:  2009-08-20     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0421030     Medline TA:  Am J Gastroenterol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2005-13     Citation Subset:  IM    
Affiliation:
Department of Medicine, Neuroenteric Clinical Research Group, Southern Arizona VA Health Care System and University of Arizona Health Sciences Center, Tucson, Arizona 85723-0001, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Drug Administration Schedule
Duodenogastric Reflux / drug therapy*,  physiopathology
Esophageal pH Monitoring
Female
Gastroesophageal Reflux / drug therapy*,  physiopathology
Humans
Male
Middle Aged
Omeprazole / administration & dosage*
Proton Pump Inhibitors / administration & dosage*
Remission Induction
Treatment Failure
Chemical
Reg. No./Substance:
0/Proton Pump Inhibitors; 73590-58-6/Omeprazole

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Reassessment of intrinsic factor and parietal cell autoantibodies in atrophic gastritis with respect...
Next Document:  High prevalence of fatty acid synthase expression in colorectal cancers in Middle Eastern patients a...